Inhibition of cytochrome P450 (CYP450) enzymes is the most common mechanism leading to drug–drug interactions [ 4 ]
045575 Six proton pump inhibitors (PPIs), omeprazole, lansoprazole, esomeprazole, dexlansoprazole, pantoprazole, and rabeprazole, were
Since the slightly increased area under the concentration-time curve (AUC) of cisapride could be explained as an inhibition of CYP2C19, the data on these 3 CYP3A4
5 mg of CAMZYOS because a lower CAMZYOS once-daily dose is not available [see
K
The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its
esomeprazole dose if dose >40 mg, especially if also combined w/ a CYP2C19 inhibitor: combo may incr
e
Backman1,2,* In vitro, esomeprazole is a time-dependent inhibitor of CYP2C19
The year 2001 saw the market launch of esomeprazole, the first inhibitor produced in the form of an optical isomer and being a left-handed (S)-isomer of omeprazole
1, 2 Omeprazole, its isomers and other proton pump inhibitors are metabolized by the cytochrome P450 enzymes CYP2C19 and CYP3A4
8 vs
Omeprazole and esomeprazole inhibit CYP2C19, thus inhibiting their own metabolism with chronic dosing
Both CYP inhibitors also caused an increase in the active moiety exposure Esomeprazole did not interact with the CYP3A4 substrates clarithromycin (2 studies) or quinidine
Concomitant administration of esomeprazole and a CYP3A4 inhibitor In vivo, inhibition of CYP3A4 increases serum sertraline concentrations [60, 61] while possible CYP3A4 induction by carbamazepine decreases sertraline concentrations [62, 63]
However, dose adjustment of esomeprazole, with normal dosage, is not required
Esomeprazole, a proton pump inhibitor, P-gp inhibitor drugs increase the total exposure to less than twofold, while CYP3A4 inhibition causes a minimal additional change in exposure
Inhibition of the CYP3A4-mediated metabolism of PPIs: Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure
These classifications are based upon US Omeprazole is a proton-pump inhibitor used to manage and treat several conditions, including uncomplicated heartburn, peptic ulcer disease, gastrointestinal reflux disease, Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis, erosive esophagitis, gastric ulcers, and helicobacter pylori infection
Because most PPIs are predominantly metabolized by cytochrome P450 (CYP) 2C19 and have CYP2C19 inhibitory effects, the intake of PPIs in combination with